RF30 | PSAT148 Bone Mass and Body Composition Analysis in Transgender Men: A 1 Year Follow Up

INTRODUCTION: Sex steroid hormones play a key role in bone health, however medical therapies for gender dysphoria lead to hormonal changes. PURPOSE: Understanding the changes in bone mass and body composition is extremely important, because this treatment will be carried out over a long period of time. METHODS: In a prospective study, we included 19 transgender men (female-to-male transgender persons) before treatment and after 1 year of treatment with undecanoate (1000 mg i.m./12 weeks). Bone densitometry model Hologic-Discovery performed at baseline and after 6, 12 months of therapy. All participants signed the TCLE, project approved by CEP-CAAE: 36823220.6.0000.0062. RESULTS: Analysis of 19 transgender men with a mean age of 24 years +/- 10 years. LS-BMD (lumbar spine) at initial time (0m) 1,075±0,238 g/cm(2) and after 6 months (6m) 1,044±0,117 g/cm(2) and 12 months (12m) after 1,052±0.122 g/cm(2), p=0.21; FN-BMD (Femur Neck) 0m= 0.904±0.121 g/cm(2); 6m= 0.918±0.108 g/cm(2) and 12m= 0.905±0.107 g/cm(2); p=0.90. TH-BMD (Total Hip) 0m=1.017±0.139 g/cm(2); and 6m= 1.023±0.134 g/cm(2); 12m= 1.032±0.136g/cm(2); p=0.05. About body composition: the percentage of body fat: 0m=38.8±6.7%, 6m=34.5±7.1%; 12m=34.9±9.0; p=0.09; android/gynecoid ratio: 0.93±0.16, 6m=0.94±0.17; 12m=0.94±0.18 p=0.06, VAT mass (cm3) 431.8±262.1, 6m= 401.8±298.6, 12m= 455.5±322.7 and Lean/Height(2) (kg/m(2)) 0m= 15.52±3.24 6m= 16.15±2.19 kg/ m(2); 12m= 15.86±2.22 kg/m(2); p<0.01 and Appen. Lean/Height(2) (kg/m(2)) 6.92±1.74, 6m= 7.32±1.22 and 12m= 7.31±1.07; p<0.01 CONCLUSION: In 1 year of hormone therapy with testosterone, we did not observe significant differences in bone mass, but in body composition there was a gain in appendicular lean mass. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m., Monday, June 13, 2022 1:00 p.m. - 1:05 p.m.